Detalles de la búsqueda
1.
Time and productivity loss associated with immunotherapy infusions for the treatment of melanoma in the United States: a survey of health care professionals and patients.
BMC Health Serv Res
; 23(1): 136, 2023 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36759810
2.
Real-world clinical outcomes of patients with stage IIB or IIC cutaneous melanoma treated at US community oncology clinics.
Future Oncol
; 18(33): 3755-3767, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36346064
3.
Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced melanoma.
Future Oncol
; 17(20): 2683-2692, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33783230
4.
Outcomes of retreatment with anti-PD-1 monotherapy after response to first course in patients with cutaneous melanoma.
Future Oncol
; 16(20): 1441-1453, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32410465
5.
Treatment and overall survival among anti-PD-1-exposed advanced melanoma patients with evidence of disease progression.
Immunotherapy
; 14(4): 201-214, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34870445
6.
HER2 expression in urothelial carcinoma, a systematic literature review.
Front Oncol
; 12: 1011885, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36338710
7.
Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions.
Melanoma Res
; 32(6): 393-404, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36223314
8.
Cost-Effectiveness of Pembrolizumab Versus Carboplatin and Paclitaxel in Patients With Unresectable or Metastatic Melanoma After First-Line Treatment in China.
Value Health Reg Issues
; 27: 99-107, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34922053
9.
Burden and Risk Factors of Brain Metastases in Melanoma: A Systematic Literature Review.
Cancers (Basel)
; 14(24)2022 Dec 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36551594
10.
Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases.
Front Oncol
; 12: 1025664, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36568199
11.
Current Treatment Approaches and Global Consensus Guidelines for Brain Metastases in Melanoma.
Front Oncol
; 12: 885472, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35600355
12.
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany.
Cancers (Basel)
; 14(7)2022 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35406577
13.
Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis.
J Immunother
; 44(6): 224-233, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33734142
14.
Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in Argentina.
Oncol Ther
; 9(1): 167-185, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33624271
15.
Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database.
Immunotherapy
; 13(11): 905-916, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34074114
16.
An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
Cancer Med
; 9(21): 7863-7878, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32871054
17.
Epidemiology and survival outcomes in stages II and III cutaneous melanoma: a systematic review.
Melanoma Manag
; 7(1): MMT39, 2020 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32399177
18.
An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.
Clin Drug Investig
; 40(7): 629-643, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32418051
19.
Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers.
J Med Econ
; 23(2): 132-138, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-31750751
20.
An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma.
J Drug Assess
; 8(1): 135-145, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31489255
Resultados
1 -
20
de 20
1
Próxima >
>>